TPO受体激动剂对比白细胞介素-11治疗血液肿瘤化疗后血小板减少症的单中心数据分析OA

Objective:To compare the efficacy,safety,and pharmacoeconomic profiles of thrombopoietin receptor agonists(TPO-RAs)versus recombinant human interleukin-11(rhIL-11)in the treatment of chemotherapy-induced thrombocytopenia(CIT)in patients with hematologic malignancies.Methods:A total of 87 patients with CIT secondary to hematologic malignancies were retrospectively enrolled and divided into a TPO-RAs group(n=43)and an rhIL-11 group(n=44)according to treatment regimen.Platelet recovery time,response rate,adverse events,and treatment costs were compared between the two groups.Results:Platelet counts increased with treatment time in both groups,and there was no statistically significant difference in the trend of change between the groups(P＞0.05).There was no statistically significant difference in platelet counts between the two groups at each time point after treatment(P＞0.05).The attainment rates of platelet count recovery to＞50 × 109/L,＞75 × 109/L,and＞100 × 109/L in the TPO-RAs group were 83.7％,76.7％,and 60.5％,respectively,while those in the rhIL-11 group were 75.0％,65.9％,and 52.3％,respectively.There was no statistically significant difference in attainment rate and median recovery time between the two groups(P＞0.05).Multivariate Cox regression showed that baseline platelet level was an independent influencing factor for platelet recovery(P＜0.05),while treatment group did not show statistical significance with platelet recovery(P＞0.05).The incidence of adverse events in the TPO-RAs group was lower than that in the rhIL-11 group(P＜0.05).In the cost analysis,there was no statistically significant difference in total cost between the two groups(P＞0.05),but the total cost of the eltrombopag subgroup was the lowest in value.Conclusion:TPO-RAs and rhIL-11 demonstrate comparable efficacy in treating CIT in hematologic malignancies,whereas TPO-RAs offer a superior safety profile.Eltrombopag shows a numerical advantage in treatment cost.Baseline platelet level may serve as a reference indicator for assessing recovery potential.